Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy

Venetoclax (VEN) inhibits the prosurvival protein BCL2 to induce apoptosis and is a standard therapy for chronic lymphocytic leukemia (CLL), delivering high complete remission rates and prolonged progression-free survival in relapsed CLL but with eventual loss of efficacy. A spectrum of subclonal ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Thijssen, Rachel, Tian, Luyi, Anderson, Mary Ann, Flensburg, Christoffer, Jarratt, Andrew, Garnham, Alexandra L., Jabbari, Jafar S., Peng, Hongke, Lew, Thomas E., Teh, Charis E., Gouil, Quentin, Georgiou, Angela, Tan, Tania, Djajawi, Tirta M., Tam, Constantine S., Seymour, John F., Blombery, Piers, Gray, Daniel H.D., Majewski, Ian J., Ritchie, Matthew E., Roberts, Andrew W., Huang, David C.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653037/
https://www.ncbi.nlm.nih.gov/pubmed/35709339
http://dx.doi.org/10.1182/blood.2022016040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653037/
https://www.ncbi.nlm.nih.gov/pubmed/35709339
http://dx.doi.org/10.1182/blood.2022016040

Ejemplares similares